Verastem Oncology (VSTM) Tops Q2 EPS by 12c
Tweet
Share
E-mailGet Alerts VSTM Hot Sheet
Join SI Premium – FREE
Verastem Oncology (NASDAQ: VSTM) reported Q2 EPS of ($0.31), $0.12 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $40.07 million versus the consensus estimate of $23.09 million.
For earnings history and earnings-related data on Verastem Oncology (VSTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GameStop CEO Cohen buys 1.15M shares
- Lupin (LPC:IN) PT Lowered to INR2,500 at HSBC
- Jefferies Starts Oversea-Chinese Banking Corp Ltd (OCBC:SP) (OVCHF) at Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
